AI주식인사이트AI Stock Insight
C

HLB테라퓨틱스

115450KOSDAQ기타 전문 도매업

42.6 / 100

Reference Date: 2026-06-10

Financial Score9.5 / 40
News Sentiment19.1 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 27.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Therapeutics operates three core business divisions: biopharma, cold chain, and electronics. Through numerous mergers and acquisitions since 2013, the company has diversified its business, and after divesting its electronics division in 2024, it continues to transition toward a biopharma-focused structure. Its main revenue streams come from vaccine pharmaceuticals and distribution fees.

Number of Employees

50people

Average Salary

48.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 13.364.0Point
PBR
1.28Industry Average 0.580.0Point

2.2x industry avg (risky)

ROE
-5.44Industry Average 2.090.0Point

Well below industry avg

Debt Ratio
16.44Industry Average 7.870.0Point

2.1x industry avg (risky)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲33.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -6.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 2,520Won52-week high 9,10852-week low 2,424
1-month return0.0Point

1m -27.17% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-06-09
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
  • Neutral전환가액의조정2026-06-04
  • Neutral주식등의대량보유상황보고서(일반)2026-06-02
  • Neutral분기보고서 (2026.03)2026-05-15